Facial Resurfacing for Nonmelanoma Skin Cancer Prophylaxis

Hantash, Basil M.; Stewart, Daniel B.; Cooper, Zachary A.; Rehmus, Wingfield; Koch, R.; Swetter, Susan M.

doi:10.1001/archderm.142.8.976

Cited by 88 publications

(121 citation statements)

References 32 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4] However, encouraging data are emerging with nonablative technologies, such as the 1550-nm fractionated erbium-doped fiber laser (Fraxel re :store, Solta Medical) used for treatment of facial AK by Katz et al 5 In their study, 14 men with multiple AK received 5 treatments with 6-month follow-up. Although AK reduction rates remained high at 1 month, the clearance rates declined at 3 and 6 months posttreatment.…”

Section: Discussionmentioning

confidence: 99%

1927-nm Fractional resurfacing of facial actinic keratoses: A promising new therapeutic option

Weiss

Brauer

Anolik

et al. 2013

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

1927-nm Fractional resurfacing of facial actinic keratoses: A promising new therapeutic option

Weiss

Brauer

Anolik

et al. 2013

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…[74][75][76] Supportive data are limited. Medium-depth chemical peeling is an operator-dependent technique, and patients should be referred to a specialist with experience in the procedure.…”

Section: Other Therapiesmentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

et al. 2015

View full text Add to dashboard Cite

Background Actinic keratosis (AK) and cheilitis (AC) are lesions that develop on photodamaged skin and may progress to form invasive squamous cell carcinomas (SCCs). Objective To provide guidance to Canadian health care practitioners regarding management of AKs and ACs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results Treatment of AKs allows for secondary prevention of skin cancer in sun-damaged skin. Because it is impossible to predict whether a given AK will regress, persist, or progress, AKs should ideally be treated. This chapter discusses options for the management of AKs and ACs. Conclusions Treatment options include surgical removal, topical treatment, and photodynamic therapy. Combined modalities may be used in case of inadequate response. AKs are particularly common following the longterm immunosuppression in organ transplant patients, who should be monitored frequently to identify emerging lesions that require surgery.

show abstract

“…10 The fractionated laser used in our study leaves areas surrounding each MTZ untreated, which may J AM ACAD DERMATOL VOLUME 65, NUMBER 2 contain dysplastic cells. Hantash et al 10 reported a 92% reduction in the number of AKs 2 months after CO 2 laser ablation.…”

Section: Discussionmentioning

confidence: 99%

“…1 Cryotherapy with liquid nitrogen is the most common treatment method because of its low cost, ease of use, and efficacy. 2,3 Topical chemotherapy (5-fluorouracil, imiquimod, diclofenac), [4][5][6][7] light-based therapy including photodynamic therapy (PDT) with aminolevulinic acid (ALA), 8,9 and ablative laser therapy (carbon dioxide [CO 2 ] and erbium:yttrium-aluminum-garnet) [10][11][12][13] are effective for multiple or widespread AKs. Ablation of the epidermis results in a clinical and histologic cure of the AKs but is complicated by a prolonged recovery time.…”

mentioning

confidence: 99%